Oxford Biomedica PLC Director Dealings / Market Share Purchase (2933M)
September 13 2019 - 4:53AM
UK Regulatory
TIDMOXB
RNS Number : 2933M
Oxford Biomedica PLC
13 September 2019
Director Dealings / Market Share Purchase
Oxford, UK - 13 September 2019: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, today announces that Vulpes Testudo Fund, a person
closely associated with Martin Diggle, Non-Executive Director, has
purchased 17,953 ordinary shares of 50p each ("Ordinary Shares") in
the Company on 12 September 2019 on the London Stock Exchange at a
price of 576.8p per share. Following this purchase Vulpes
Testudo/Vulpes Life Sciences Fund holds 11,658,640 ordinary shares
representing 15.2% of the Company.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of Ordinary Shares purchased.
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Vulpes Testudo Fund
2. Reason for the notification
a. Position/status Person closely associated with Martin
Diggle, Non-Executive Director
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford Biomedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford Biomedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Purchase of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP5.77 17,953
e. Aggregated information 17,953
* Aggregated volume GBP5.76828385
GBP103,558.00
* Price
* Aggregated total
f. Date of the transaction 2019-09-12
g. Place of the transaction London Stock Exchange, Main Market (XLON)
The issued share capital of the Group is 76,767,971 ordinary 50p
shares.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the
UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in
other potential gene and cell therapy products. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more
than 480 people. Further information is available at
www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUOVKRKRAKARR
(END) Dow Jones Newswires
September 13, 2019 05:53 ET (09:53 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024